摘要
目的探讨对支气管哮喘(BA)患者联用复方异丙托溴铵和复方甲氧那明的效果。方法选取2020年5月至2021年5月新乡市第二人民医院收治的86例BA患者。依据随机抽签法分为对照组和观察组,各43例。患者均接受常规治疗。基于此,对照组患者接受复方异丙托溴铵治疗,观察组患者接受复方甲氧那明联合复方异丙托溴铵治疗,持续用药7 d。比较两组临床症状和体征消失时间以及不良反应发生情况。比较两组治疗前和治疗7 d的用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)、白细胞介素-6(IL-6)水平。结果观察组气喘、咳嗽、湿啰音和哮鸣音的消失时间短于对照组(P<0.05)。治疗7 d,两组FVC、FEV_(1)、FEV_(1)/FVC水平均高于治疗前,观察组FVC、FEV_(1)、FEV_(1)/FVC水平高于对照组(P<0.05)。治疗7 d,两组血清TNF-α、IL-6及IFN-γ水平低于治疗前,观察组血清TNF-α、IL-6及IFN-γ水平低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论采用复方异丙托溴铵联合复方甲氧那明治疗支气管哮喘患者,可改善患者肺功能,降低炎症因子水平,缩短临床症状消失时间。
Objective To investigate the effect of combined use of compound ipratropium bromide and compound methoxyphenamine in patients with bronchial asthma(BA).Methods A total of 86 patients with BA treated in Xinxiang Second People’s Hospital from May 2020 to May 2021 were selected.They were divided by a random drawing lots method into control group and observation group,with 43 cases in each group.All patients were treated with routine treatment.Based on this,the patients in control group were treated with compound ipratropium bromide,and the patients in observation group were treated with compound methoxyamine combined with compound ipratropium bromide,continuous medication for 7 days.The disappearance time of clinical symptoms and signs and adverse reactions were compared between the two groups.The forced vital capacity(FVC),forced expiratory volume in the first second(FEV_(1)),FEV_(1)/FVC,tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)and interleukin-6(IL-6)were compared between the two groups before and 7 days after treatment.Results The disappearance time of asthma,cough,wet rale and wheezing in observation group was shorter than that in control group(P<0.05).After treatment for seven days,the levels of FVC,FEV_(1) and FEV_(1)/FVC in both groups were higher than those before treatment,while the levels of FVC,FEV_(1) and FEV_(1)/FVC in observation group were higher than those in control group(P<0.05).Seven days after treatment,the levels of serum TNF-α,IL-6 and IFN-γin the two groups were lower than those before treatment,while those in observation group were lower than those in control group(P<0.05).There was no statistical difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compound ipratropium bromide combined with compound methoxyphenamine can improve pulmonary function,reduce the level of inflammatory factors and shorten the disappearance time of clinical symptoms in patients with BA.
作者
尚宇红
栾淑萍
SHANG Yuhong;LUAN Shuping(a.Department of Pharmacy,Xinxiang Second People’s Hospital,Xinxiang 453000,China;b.Department of Tumor Hematology,Xinxiang Second People’s Hospital,Xinxiang 453000,China)
出处
《河南医学研究》
CAS
2021年第30期5683-5686,共4页
Henan Medical Research
关键词
支气管哮喘
复方异丙托溴铵
复方甲氧那明
肺功能
炎症因子
bronchial asthma
compound ipratropium bromide
compound methoxyphenamine
pulmonary function
inflammatory factor
